A detailed history of Alliancebernstein L.P. transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 11,250 shares of CTXR stock, worth $7,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,250
Previous 11,250 -0.0%
Holding current value
$7,650
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.65 - $1.25 $7,312 - $14,062
-11,250 Reduced 50.0%
11,250 $7,000
Q2 2023

Aug 15, 2023

BUY
$1.08 - $1.65 $24,300 - $37,125
22,500 New
22,500 $27,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.87 $184,184 - $391,391
-209,300 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$1.38 - $1.89 $965 - $1,323
700 Added 0.34%
209,300 $375,000
Q2 2021

Jul 30, 2021

BUY
$1.51 - $4.23 $314,986 - $882,378
208,600 New
208,600 $726,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $99.4M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.